SPOTLIGHT -
September 25th 2025
Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.
Explore the challenges and strategies of deprescribing in geriatric psychiatry to enhance patient safety and reduce polypharmacy risks.
September 22nd 2025
Mass shootings are often misattributed to mental illness, overshadowing the real issues of grievance, radicalization, and access to weapons.
September 21st 2025
Esketamine nasal spray shows significant improvement in emotional blunting for treatment-resistant depression, offering hope for affected patients.
September 18th 2025
A groundbreaking trial reveals ANK3 as a potential genetic predictor for liafensine's effectiveness in treating resistant depression.